- Home
- SKYE vs XTNT Comparison
SKYE vs XTNT Comparison
Compare SKYE & XTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- XTNT
- Stock Information
- Founded
- SKYE 2012
- XTNT N/A
- Country
- SKYE United States
- XTNT United States
- Employees
- SKYE N/A
- XTNT N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- XTNT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SKYE Health Care
- XTNT Health Care
- Exchange
- SKYE Nasdaq
- XTNT Nasdaq
- Market Cap
- SKYE 121.8M
- XTNT 99.4M
- IPO Year
- SKYE N/A
- XTNT N/A
- Fundamental
- Price
- SKYE $1.33
- XTNT $0.76
- Analyst Decision
- SKYE Strong Buy
- XTNT
- Analyst Count
- SKYE 5
- XTNT 0
- Target Price
- SKYE $14.75
- XTNT N/A
- AVG Volume (30 Days)
- SKYE 1.8M
- XTNT 223.7K
- Earning Date
- SKYE 11-06-2025
- XTNT 11-11-2025
- Dividend Yield
- SKYE N/A
- XTNT N/A
- EPS Growth
- SKYE N/A
- XTNT N/A
- EPS
- SKYE N/A
- XTNT N/A
- Revenue
- SKYE N/A
- XTNT $127,766,000.00
- Revenue This Year
- SKYE N/A
- XTNT $13.03
- Revenue Next Year
- SKYE N/A
- XTNT N/A
- P/E Ratio
- SKYE N/A
- XTNT N/A
- Revenue Growth
- SKYE N/A
- XTNT 15.16
- 52 Week Low
- SKYE $1.14
- XTNT $0.33
- 52 Week High
- SKYE $5.96
- XTNT $0.84
- Technical
- Relative Strength Index (RSI)
- SKYE 27.04
- XTNT 60.25
- Support Level
- SKYE $1.50
- XTNT $0.68
- Resistance Level
- SKYE $1.76
- XTNT $0.84
- Average True Range (ATR)
- SKYE 0.24
- XTNT 0.06
- MACD
- SKYE -0.15
- XTNT 0.01
- Stochastic Oscillator
- SKYE 0.68
- XTNT 60.34
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About XTNT Xtant Medical Holdings Inc.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.